Article
Medicine, General & Internal
Tzu-Yuan Wang, Hsueh-Chou Lai, Hsin-Hung Chen, Mei-Lin Wang, Ming-Chia Hsieh, Chwen-Tzuei Chang, Rong-Hsing Chen, Chun-Wei Ho, Yi-Chin Hung, Juei-Yu Tseng, Cheng-Li Lin, Chia-Hung Kao
Summary: In patients with newly diagnosed T2DM, the risk of PLA is high, especially in younger, male patients with a duration of DM <2 years. The most common causative agent of PLA in T2DM patients is Klebsiella pneumoniae (KP), and those with gallstones and cholecystitis have a higher risk of PLA.
FRONTIERS IN MEDICINE
(2021)
Article
Endocrinology & Metabolism
Lulu Song, Xiaomu Kong, Zhaojun Yang, Jinping Zhang, Wenying Yang, Bo Zhang, Xiaoping Chen, Xin Wang
Summary: The study aimed to compare the effect of acarbose and metformin on reducing low-grade albuminuria in newly diagnosed Chinese T2DM patients. Acarbose was found to significantly lower the urinary albumin/creatinine ratio compared to metformin, independent of improvements in hyperglycemia, blood pressure, body weight, and triglycerides. This effect remained consistent across subgroups stratified by eGFR, blood glucose level, sex, or uACR level.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2021)
Article
Multidisciplinary Sciences
A. G. Unnikrishnan, R. K. Sahay, Uday Phadke, S. K. Sharma, Parag Shah, Rishi Shukla, Vijay Viswanathan, S. K. Wangnoo, Santosh Singhal, Mathew John, Ajay Kumar, Mala Dharmalingam, Subodh Jain, Shehla Shaikh, Willem J. Verberk
Summary: Through studying newly diagnosed T2DM patients in India, it is found that they have high cardiovascular disease risk. This indicates the need for further extension of ASCVD risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases.
Article
Cardiac & Cardiovascular Systems
Christine Gyldenkerne, Martin Bodtker Mortensen, Johnny Kahlert, Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Henrik Toft Sorensen, Reimar Wernich Thomsen, Michael Maeng
Summary: Newly diagnosed type 2 diabetes mellitus significantly increases the risk of cardiovascular disease in patients, especially among younger individuals. Compared to the general population, individuals with type 2 diabetes have a significantly higher 10-year risk of developing cardiovascular events, occurring at least 12 years earlier.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Respiratory System
Eunyoung Heo, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee
Summary: This retrospective cohort study showed that only the highest cumulative doses of metformin were protective against the development of TB among patients newly diagnosed with type 2 DM; lower cumulative doses of metformin did not appear to reduce the incidence of active TB infection.
BMC PULMONARY MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Rong Zhang, Quanxi Zhao, Rong Li
Summary: This study investigated predictors of acarbose therapeutic efficacy in newly diagnosed T2DM patients in China. The results showed that acarbose may be more effective in newly diagnosed T2DM patients with low FPG, low 2 h PG, and obesity.
BMC PHARMACOLOGY & TOXICOLOGY
(2022)
Article
Endocrinology & Metabolism
Chiara Zusi, Alessandro Csermely, Elisabetta Rinaldi, Kezia Bertoldo, Sara Bonetti, Maria Linda Boselli, Daniela Travia, Enzo Bonora, Riccardo C. Bonadonna, Maddalena Trombetta
Summary: The aim of this study is to evaluate the relationship between genetic variability of ADIPOQ, LEP, and LEPR genes with the glucose-insulin system and markers of subclinical atherosclerosis (ATS) in patients with newly diagnosed type 2 diabetes. The results showed that two SNPs within the ADIPOQ gene were associated with adiponectin levels. Haplotypes of ADIPOQ, LEP, and LEPR genes were associated with circulating levels of adiponectin, leptin, and markers of ATS, providing insight into the role of adipokines in glucose metabolism and atherosclerosis.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Paivi M. Paldanius, Kun Ho Yoon
Summary: In the VERIFY study conducted in Korea between 2012 and 2014, early combination (EC) treatment significantly reduced the risk of initial treatment failure compared to MET monotherapy in newly diagnosed type 2 diabetes mellitus patients, with consistently lower HbA1c levels achieved by patients receiving EC treatment.
DIABETES & METABOLISM JOURNAL
(2021)
Article
Endocrinology & Metabolism
Enzo Bonora, Maddalena Trombetta, Marco Dauriz, Corinna Brangani, Vittorio Cacciatori, Carlo Negri, Isabella Pichiri, Vincenzo Stoico, Elisabetta Rinaldi, Giuliana Da Prato, Maria Linda Boselli, Lorenza Santi, Federica Moschetta, Monica Zardini, Riccardo C. Bonadonna
Summary: In newly diagnosed type 2 diabetes, insulin resistance and beta-cell dysfunction are very common with a wide range of expression but no specific pattern of aggregation.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2022)
Article
Endocrinology & Metabolism
Rui Min, Yancheng Xu, Bocheng Peng
Summary: This study evaluated the clinical value of glycosylated hemoglobin (HbA1c) in newly diagnosed ketosis-prone type 2 diabetes (KPD). The results showed that HbA1c was correlated with ketosis, insulin, and islet function. Patients with HbA1c > 10.15% were more likely to develop KPD.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Yun Hu, Bo Ding, Yun Shen, Reng-Na Yan, Feng-Fei Li, Rui Sun, Ting Jing, Kok-Onn Lee, Jian-Hua Ma
Summary: The study found that in men with type 2 diabetes mellitus, oral metformin for one month can lower serum testosterone levels. Compared with the control group, the metformin group showed a significant decrease in testosterone levels. Further research is needed to investigate the long-term effects of metformin on testosterone in men.
Article
Pharmacology & Pharmacy
K. Tuncer Kara, M. Kizil, E. Cakmak, T. T. Yildirim, F. Kilinc, T. Kuloglu, N. Gozel
Summary: This study compares the plasma and salivary levels of Metrnl in patients newly diagnosed with type-2 diabetes who were treated with metformin for three months with those of a healthy volunteer group, and analyzes the immunoreactivity of Metrnl in salivary glands through immunohistochemical staining. The results show that plasma Metrnl levels are higher in the newly diagnosed diabetes group, and salivary Metrnl levels are higher after three months of metformin treatment. Immunohistochemical staining reveals Metrnl immunoreactivity in specific locations of the parotid and submandibular glands.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Genetics & Heredity
Rana Taheri, Faranak Kazerouni, Reza Mirfakhraei, Saeid Kalbasi, Seyedeh Zahra Shahrokhi, Ali Rahimipour
Summary: This study investigated the association of rs543159 and rs1317652 variants in the SLC22A3 gene with response to metformin monotherapy in newly diagnosed patients with T2DM. The results suggest that these genetic variations may be correlated with variability in treatment response.
Article
Medicine, General & Internal
Eleanor L. Ramos, Colin M. Dayan, Lucienne Chatenoud, Zdenek Sumnik, Kimber M. Simmons, Agnieszka Szypowska, Stephen E. Gitelman, Laura A. Knecht, Elisabeth Niemoeller, Wei Tian, Kevan C. Herold, PROTECT Study Investigators
Summary: Two 12-day courses of teplizumab in children and adolescents with newly diagnosed type 1 diabetes showed benefit with respect to the preservation of beta-cell function, but no significant differences between the groups were observed with respect to the secondary endpoints.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Anders Gummesson, Elias Bjornson, Linn Fagerberg, Wen Zhong, Abdellah Tebani, Fredrik Edfors, Caroline Schmidt, Annika Lundqvist, Martin Adiels, Fredrik Baeckhed, Jochen M. Schwenk, Per-Anders Jansson, Mathias Uhlen, Goran Bergstrom
Summary: The study found distinct protein patterns in early-stage type 2 diabetes patients, reflecting key metabolic syndrome features. These patterns improved after treatment, indicating that comprehensive protein profiling can be a useful tool in elucidating the biological effects of diabetes treatments.